Evidence map›Paper›PMID 31898964›Full record

SynthesisThe American journal of cardiology2020

Meta-analysis of the Relation of Body Mass Index to Cardiovascular Outcomes in Patients Receiving Intensive Low-Density Lipoprotein Cholesterol Lowering Therapy.

Safi U Khan, Muhammad U Khan, Haris Riaz, Paolo Raggi, Shahul Valavoor, Muhammad Zia Khan, Michalina Kołodziejczak, Muhammad Shahzeb Khan, Troy Krupica, Mohamad Alkhouli and 1 more

Open access · greenAbstract readMeta-Analysis
In one paragraph

Synthesis in The American journal of cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Safi U KhanDepartment of Medicine, West Virginia University, Morgantown, West Virginia. Electronic address: safinmc@gmail.com.
Muhammad U KhanDepartment of Medicine, West Virginia University, Morgantown, West Virginia.
Haris RiazDepartment of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.
Paolo RaggiMazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada.
Shahul ValavoorDepartment of Medicine, West Virginia University, Morgantown, West Virginia.
Muhammad Zia KhanDepartment of Medicine, West Virginia University, Morgantown, West Virginia.
Michalina KołodziejczakSystematic Investigation and Research on Interventions and Outcomes (SIRIO) MEDICINE Cardiovascular Research Network, Düsseldorf, Germany; Cardiovascular Institute, Ludwik Rydygier Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
Muhammad Shahzeb KhanDepartment of Medicine, John H. Stroger J. Hospital of Cook County, Chicago, Illinois.
Troy KrupicaDepartment of Medicine, West Virginia University, Morgantown, West Virginia.
Mohamad AlkhouliDepartment of Cardiovascular Medicine, West Virginia University, Morgantown, West Virginia.
Eliano P NavareseSystematic Investigation and Research on Interventions and Outcomes (SIRIO) MEDICINE Cardiovascular Research Network, Düsseldorf, Germany; Cardiovascular Institute, Ludwik Rydygier Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland; Interventional Cardiology and Cardiovascular Medicine Research, Mater Dei Hospital, Bari, Italy.
West Virginia University · USNicolaus Copernicus University · PLCleveland Clinic · USUniversity of Alberta · CA

Funding

West Virginia IDEA-CTRU54GM104942 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Laura F. Gibson · 2012 to 2026
$81.0M
NIGMS NIH HHS U54 GM104942
6 · The paper itself

Abstract

The impact of body mass index (BMI) on cardiovascular outcomes in patients receiving intensive low-density lipoprotein cholesterol (LDL-C) lowering therapy is uncertain. We performed meta-analysis of 29 randomized controlled trials using PubMed, Embase, and CENTRAL through April 2019. Therapies were grouped as more intensive LDL-C lowering therapy (statins, ezetimibe + statin or PCSK9 inhibitors) and less intensive LDL-C lowering therapy (less potent active control or placebo). Random effects meta-regressions and meta-analyses were performed to evaluate association of BMI with cardiovascular endpoints. In 265,766 patients, for every 1 kg/m

Indexed as

Anticholesteremic AgentsBody Mass IndexCardiovascular DiseasesCause of DeathCholesterol, LDLComorbidityDyslipidemiasEzetimibeHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMortalityMyocardial InfarctionMyocardial RevascularizationObesityPCSK9 InhibitorsProportional Hazards ModelsAnticholesteremic AgentsCholesterol, LDLEzetimibeHydroxymethylglutaryl-CoA Reductase InhibitorsPCSK9 Inhibitors

Identifiers

PMID31898964
PMCPMC7397555
OpenAlexW2995442437

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.